Latest news
ICYMI: EU Approves Upadacitinib for Severe Alopecia as US Review Remains Pending - Dermatology TimesDermatology Times · Thu, 06 Aug 2026 13:39:20 GMTQTTB: Bempikibart shows strong efficacy and safety in severe alopecia areata, supporting Phase 3 advancement - TradingViewTradingView · Wed, 05 Aug 2026 11:39:41 GMTQ32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - TradingViewTradingView · Wed, 05 Aug 2026 10:59:00 GMTLilly Korea marks expanded treatment access for dermatology and immunology patients - koreabiomed.comkoreabiomed.com · Fri, 31 Jul 2026 03:04:16 GMTEarlier JAK Inhibitor Intervention May Improve Alopecia Areata Outcomes - Dermatology TimesDermatology Times · Thu, 30 Jul 2026 19:12:46 GMTAbbVie Secures EU Approval for Rinvoq to Treat Severe Alopecia Areata - YahooYahoo · Wed, 29 Jul 2026 07:00:00 GMTAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Yahoo FinanceYahoo Finance · Wed, 29 Jul 2026 07:00:00 GMTEU first to clear AbbVie's Rinvoq for alopecia areata - pharmaphorum.compharmaphorum.com · Wed, 29 Jul 2026 07:00:00 GMT